A subtle but practice-changing takeaway from the COMPETE study is that patients did not receive concurrent somatostatin analogs. This suggests that continuing this supportive therapy may not be essential for patients with non-functioning neuroendocrine tumors undergoing PRRT, potentially simplifying treatment and reducing patient burden.

In ambiguous cases, immunohistochemistry showing the loss of the RB1 protein is a powerful indicator of a poorly differentiated neuroendocrine carcinoma (NEC). This helps distinguish NECs from high-grade neuroendocrine tumors or adenocarcinomas with neuroendocrine features, a critical distinction for prognosis and treatment.

In community SCLC care, molecular strategies are not monolithic. Genomic alteration testing (NGS) is ready for immediate use and can identify targets today. In contrast, neuroendocrine subtyping is still investigational and not yet clinically actionable, pending results from research studies.

The novel target DLL3 is a promising avenue for treating NECs, but its therapeutic efficacy is highly dependent on expression levels. Early trial data for a DLL3 T-cell engager showed a 40% response rate in high-expressing tumors versus just 3% in low-expressors, mandating biomarker testing for patient selection.

The technology and breadth of molecular testing panels for GIST are rapidly evolving. A patient whose tumor tested negative for driver mutations in the past should be considered for re-testing with current, broader panels. This may uncover previously undetectable alterations like FGFR translocations and open up new treatment options.

Despite widespread use in oncology, immunotherapy has limited efficacy in extrapulmonary NEC. Real-world data for combination CTLA-4 and PD-1 inhibitors show response rates around 15%, with sustained responses in less than 10% of patients. This highlights the urgent need for novel therapeutic approaches beyond checkpoint inhibition.

Contrary to common belief, HER2 can be expressed or amplified in prostate cancer, particularly in subtypes with neuroendocrine features. This creates a rare but actionable target, with reported complete responses to HER2-directed therapies like TDXD, highlighting the need for broader genomic testing.

The molecular marker INI-1 loss, while characteristic of epithelioid sarcoma, is not pathognomonic. Other malignancies, like epithelioid angiosarcoma, can also have this finding. Clinicians must integrate molecular data with the patient's age and clinical presentation to confirm the diagnosis, sometimes requiring a re-biopsy in atypical cases.

The primary site of a neuroendocrine neoplasm offers strong diagnostic clues. For example, tumors in the esophagus or gallbladder are almost always poorly-differentiated NECs, while those in the mid-colon are also typically NECs. This site-specificity serves as a powerful diagnostic heuristic for clinicians.